Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Empowering Community Cancer Care: Importance of Collaboration

October 23rd 2024

In this episode of OncChats: Empowering Community Cancer Care, experts discuss the significance of community-based cancer care, emphasizing that most cancers are diagnosed locally and highlighting the importance of collaboration between primary care physicians and specialists to provide optimal education and treatment.

Acalabrutinib Plus Venetoclax/Rituximab Yields 100% ORR in Treatment-Naive Mantle Cell Lymphoma

October 22nd 2024

Acalabrutinib plus venetoclax and rituximab generated a 100% response rate in treatment-naive mantle cell lymphoma.

Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Guidance and Future Plans

October 21st 2024

In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.

Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Prophylactic Measures

October 21st 2024

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss the need for continued evaluation of prophylactic treatments like tocilizumab and antimicrobial measures for bispecific T-cell engagers.

Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Management Strategies

October 21st 2024

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts emphasize the need for comprehensive patient education, effective communication, and specific safety protocols to manage patients receiving bispecific T-cell engagers.

Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Awareness of AEs

October 21st 2024

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss the challenges and strategies in managing bispecific T-cell engagers in the realm of cancer, emphasizing the importance of community and tertiary care collaboration to handle unique AEs like CRS and the need for well-defined protocols.

Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Overview

October 21st 2024

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss bispecific T-cell engagers, highlighting their effectiveness in treating hematologic malignancies like multiple myeloma, their potential use in solid tumors, and the importance of managing unique toxicities.

Frontline Tislelizumab/Chemo Approaches EU Approval for Gastric/GEJ Adenocarcinoma and ESCC

October 21st 2024

The European Medicines Agency has recommended extended authorization for frontline tislelizumab plus chemotherapy for GEJ adenocarcinoma and ESCC.

Assay Predicts Response to Neoadjuvant Atezolizumab Plus Chemotherapy in TNBC

October 13th 2024

The DetermaIO gene expression test was predictive of responses to neoadjuvant atezolizumab plus chemotherapy in early-stage triple-negative breast cancer.

OncLive’s September Roundup of Key FDA Approvals in Oncology

October 4th 2024

Here is your snapshot of all treatment options that the FDA approved in September 2024.

FDA Grants Fast Track Status to VLS-1488 for Platinum-Resistant High-Grade Serous Ovarian Cancer

October 3rd 2024

The KIF18A inhibitor VLS-1488 has received fast track designation from the FDA for platinum-resistant high-grade serous ovarian cancer.

MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma

October 2nd 2024

MRD negativity was sustained at 1 year following the cessation of maintenance lenalidomide in multiple myeloma.

Locally Produced CAR T-Cell Therapy Elicits 92% ORR in Relapsed/Refractory Myeloma

October 2nd 2024

The second-generation, BCMA-directed CAR T-cell therapy HBI0101 led to an objective response rate of 92% in patients with relapsed/refractory multiple myeloma.

Bria-IMT Plus Immunotherapy Shows Early Promise in Breast Cancer Brain Metastasis

October 2nd 2024

Bria-IMT plus an immune checkpoint inhibitor completely resolved a breast cancer metastasis and shrunk an eye-bulging orbital lesion in 1 patient.

DCISionRT Biosignature Identifies Residual Recurrence Risk in HER2(3+) Breast Cancer

October 2nd 2024

DCISionRT identified patients with HER2-positive breast cancer at higher risk of residual disease following breast-conserving surgery plus radiotherapy.

Neoantigen-Directed GRANITE Immunotherapy Improves PFS as Maintenance in MSS mCRC

October 2nd 2024

Maintenance with GRANITE plus fluoropyrimidine, bevacizumab, and checkpoint inhibitors improved PFS vs fluoropyrimidine plus bevacizumab alone in MSS mCRC.

Cilta-Cel Shows Real-World Feasibility and Efficacy With Acceptable Safety in R/R Myeloma

October 1st 2024

Cilta-cel elicits high response rates with an acceptable toxicity profile in a real-world population of patients with relapsed/refractory multiple myeloma.

BMS-986393 Shows First-In-Class Potential in Relapsed/Refractory Multiple Myeloma

October 1st 2024

The GPRC5D-targeted CAR T-cell therapy BMS-986393 led to an objective response rate of 96% in patients with relapsed/refractory multiple myeloma.

Daratumumab Plus RVd as Induction Therapy Improves Responses, Survival in Newly Diagnosed Myeloma

October 1st 2024

The data are part of the largest reported cohorts of consecutive and uniformly treated real-world patients with newly diagnosed multiple myeloma.

FDA Approval Sought for Subcutaneous Daratumumab Plus VRd in Transplant-Ineligible or -Deferred, Newly Diagnosed Myeloma

September 30th 2024

A sBLA has been submitted to the FDA for subcutaneous daratumumab plus VRd in ASCT-ineligible or -deferred multiple myeloma.